Wellington Management Group LLP Reduces Holdings in Boston Scientific Corporation $BSX

Wellington Management Group LLP lowered its position in shares of Boston Scientific Corporation (NYSE:BSX) by 18.8% during the second quarter, Holdings Channel reports. The firm owned 15,301,828 shares of the medical equipment provider’s stock after selling 3,531,578 shares during the quarter. Wellington Management Group LLP’s holdings in Boston Scientific were worth $653,082,000 as of its most recent filing with the SEC.

Other large investors have also recently made changes to their positions in the company. FWL Investment Management LLC purchased a new stake in Boston Scientific in the second quarter valued at approximately $26,000. Swiss RE Ltd. acquired a new position in shares of Boston Scientific in the 4th quarter valued at $26,000. Garton & Associates Financial Advisors LLC purchased a new stake in Boston Scientific in the 4th quarter valued at $26,000. Sfam LLC acquired a new stake in Boston Scientific during the 4th quarter worth $29,000. Finally, Cresta Advisors Ltd. acquired a new stake in Boston Scientific during the 4th quarter worth $33,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Trading Up 0.3%

Shares of Boston Scientific stock opened at $46.82 on Friday. The company has a 50-day moving average of $46.56 and a two-hundred day moving average of $56.65. Boston Scientific Corporation has a 12-month low of $42.20 and a 12-month high of $109.50. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The stock has a market cap of $67.85 billion, a PE ratio of 18.96, a price-to-earnings-growth ratio of 1.02 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. The business had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company’s revenue was up 7.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, research analysts anticipate that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific announced that its Board of Directors has approved a share repurchase program on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s board of directors believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on BSX shares. Mizuho reduced their target price on shares of Boston Scientific from $90.00 to $70.00 and set an “outperform” rating for the company in a report on Wednesday, July 15th. TD Cowen reaffirmed a “buy” rating and set a $56.00 price objective on shares of Boston Scientific in a research note on Tuesday. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $60.00 price objective on shares of Boston Scientific in a research report on Thursday, July 30th. Wall Street Zen lowered Boston Scientific from a “buy” rating to a “hold” rating in a report on Sunday, August 2nd. Finally, Needham & Company LLC decreased their price target on Boston Scientific from $77.00 to $57.00 and set a “buy” rating for the company in a report on Wednesday, July 8th. Twenty-four research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $71.62.

Insider Activity at Boston Scientific

In related news, Director Edward J. Ludwig purchased 5,000 shares of the company’s stock in a transaction on Friday, July 31st. The stock was bought at an average price of $45.48 per share, with a total value of $227,400.00. Following the completion of the transaction, the director owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. This represents a 19.72% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David C. Habiger acquired 2,100 shares of Boston Scientific stock in a transaction dated Wednesday, August 5th. The stock was bought at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the transaction, the director directly owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. This represents a 13.94% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders have acquired 194,522 shares of company stock valued at $9,385,210. Insiders own 0.34% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.